These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 5683667)

  • 21. The basic philosophy of federal food and drug legislation.
    LEE FP
    Food Drug Cosmet Law Q; 1948 Mar; 3(1):44-8. PubMed ID: 18859272
    [No Abstract]   [Full Text] [Related]  

  • 22. Nanotechnology in cosmetics.
    Katz LM; Dewan K; Bronaugh RL
    Food Chem Toxicol; 2015 Nov; 85():127-37. PubMed ID: 26159063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescriptions imported into the United States.
    Tenn Med; 2004 Aug; 97(8):337. PubMed ID: 15376708
    [No Abstract]   [Full Text] [Related]  

  • 24. Cosmetics and the FDA.
    Eiermann HJ
    Arch Dermatol; 1976 Jul; 112(7):1023-4. PubMed ID: 938066
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 26. The regulation of drugs and biologics: fifty years into the future.
    Kuhlik BN
    Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
    [No Abstract]   [Full Text] [Related]  

  • 27. The Federal Food and Drug Administration in the United States: born and bred in crises.
    Taylor WJ
    Int J Clin Pharmacol; 1973 Apr; 7(2):156-62. PubMed ID: 4581340
    [No Abstract]   [Full Text] [Related]  

  • 28. Cosmetics in search of a definition.
    Kanof NM
    J Am Med Womens Assoc (1972); 1974 Jul; 29(7):303-5. PubMed ID: 4376556
    [No Abstract]   [Full Text] [Related]  

  • 29. Senator proposes drug shortages law.
    Thompson CA
    Am J Health Syst Pharm; 2011 Mar; 68(6):461. PubMed ID: 21378289
    [No Abstract]   [Full Text] [Related]  

  • 30. The cosmetic ingredient review self-regulatory safety program.
    Bergfeld WF; Elder RL; Schroeter AL
    Dermatol Clin; 1991 Jan; 9(1):105-22. PubMed ID: 2022088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of cosmetics that are also drugs.
    Greff JA
    Food Drug Law J; 1996; 51(2):243-72. PubMed ID: 11820201
    [No Abstract]   [Full Text] [Related]  

  • 32. Current trends in IND-NDA procedures.
    Brilhart KB
    Bull Parenter Drug Assoc; 1971; 25(3):132-9. PubMed ID: 5093249
    [No Abstract]   [Full Text] [Related]  

  • 33. Should the FDA impose relative efficacy judgments?
    Stetler CJ
    Tex Med; 1972 Nov; 68(11):48-52. PubMed ID: 4634627
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical trials and the drug review process.
    Schmidt AM
    Chest; 1978 Jun; 73(6 Suppl):967-71. PubMed ID: 354887
    [No Abstract]   [Full Text] [Related]  

  • 35. Veterinary drug availability.
    Gloyd J
    J Am Vet Med Assoc; 1980 Apr; 176(7):611-4. PubMed ID: 7372533
    [No Abstract]   [Full Text] [Related]  

  • 36. Generally Regarded As Safe.
    Novack GD
    Ocul Surf; 2017 Jan; 15(1):152-155. PubMed ID: 27871773
    [No Abstract]   [Full Text] [Related]  

  • 37. Report suggests steps to improve safety of drug supply.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1570, 1574. PubMed ID: 21856799
    [No Abstract]   [Full Text] [Related]  

  • 38. New drugs.
    Hussar DA
    Nursing; 1981 May; 11(5):58-64. PubMed ID: 6908664
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug development, regulation, and the practice of medicine.
    Wardell WM
    JAMA; 1974 Sep; 229(11):1457-61. PubMed ID: 4408186
    [No Abstract]   [Full Text] [Related]  

  • 40. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
    Grandinetti CA; Osborne SF
    Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.